Data from a long-term Scandinavian study show that the addition of radiation to long-term androgen deprivation therapy does not affect quality of life in patients with locally advanced prostate cancer. The long-term use of the antiandrogen flutamide might, however, have negatively affected quality of life outcomes for all patients in this study.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fransson, P. et al. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol. 10, 370–380 (2009).
Widmark, A. et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373, 301–308 (2009).
Bolla, M. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360, 103–106 (2002).
D'Amico, A. V. et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292, 821–827 (2004).
Loblaw, D. A. et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J. Clin. Oncol. 25, 1596–1605 (2007).
Walsh, P. C., DeWeese, T. L. & Eisenberger, M. A. A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J. Urol. 166, 508–515 (2001).
McLeod, D. G. et al. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. J. Urol. 176, 75–80 (2006).
Sanda, M. G. et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 358, 1250–1261 (2008).
Zelefsky, M. J. et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J. Urol. 176, 1415–1419 (2006).
Kuban, D. A. et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70, 67–74 (2008).
Acknowledgements
This work was supported by the Veterans Health Administration and The Robert Wood Johnson Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Makarov, D., Penson, D. Quality of life after radiation and androgen deprivation. Nat Rev Urol 6, 477–478 (2009). https://doi.org/10.1038/nrurol.2009.168
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2009.168
